OncoMatch/Clinical Trials/NCT05123807
Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study)
Is NCT05123807 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies non-drug interventions for ovarian cancer.
The primary objective is to estimate overall survival after secondary cytoreductive surgery and HIPEC for women with recurrent primary mucinous ovarian cancer
Check if I qualifyExtracted eligibility criteria
Cancer type
Ovarian Cancer
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: hipec
Cannot have received: intraperitoneal chemotherapy
Lab requirements
Blood counts
absolute neutrophil count >1,500/mcL; platelets >100,000/mcL
Kidney function
creatinine ≤ 1.5 mg/dL
Liver function
total bilirubin ≤ 1.5 mg/dL; AST(SGOT)/ALT(SGPT) ≤ 3 X institutional upper limit of normal
absolute neutrophil count >1,500/mcL; platelets >100,000/mcL; total bilirubin ≤ 1.5 mg/dL; creatinine ≤ 1.5 mg/dL; AST(SGOT)/ALT(SGPT) ≤ 3 X institutional upper limit of normal
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- MD Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify